No Picture
News

Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Additional VK2809 Phase 2 Data to be Presented at EASL 2019; Results Demonstrate Promising Efficacy at Doses as Low as 5 mg Daily- Initiation of Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Planned… […]

No Picture
News

Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights

SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company,” “We” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in la… […]

No Picture
News

Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia

– NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept- Based on Interim Results, Company Plans to Meet with FDA to Discuss the Registration Program in Adult and Ped… […]

No Picture
News

77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy

– Bunionectomy Results Complement Opioid-Free Results from the Previously Reported Hernia Repair Study –

SAN DIEGO, March 11, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving … […]